# WIA-AUG-012: Augmentation Ethics Specification v1.0

> **Standard ID:** WIA-AUG-012
> **Version:** 1.0.0
> **Published:** 2025-12-27
> **Status:** Active
> **Authors:** WIA Human Augmentation Ethics Group

---

## Table of Contents

1. [Introduction](#1-introduction)
2. [Ethical Principles Framework](#2-ethical-principles-framework)
3. [Informed Consent Protocols](#3-informed-consent-protocols)
4. [Enhancement vs Therapy Distinction](#4-enhancement-vs-therapy-distinction)
5. [Equity and Access Considerations](#5-equity-and-access-considerations)
6. [Coercion Prevention](#6-coercion-prevention)
7. [Identity and Authenticity Preservation](#7-identity-and-authenticity-preservation)
8. [Reversibility Requirements](#8-reversibility-requirements)
9. [Vulnerable Population Protections](#9-vulnerable-population-protections)
10. [Implementation Guidelines](#10-implementation-guidelines)
11. [References](#11-references)

---

## 1. Introduction

### 1.1 Purpose

This specification establishes comprehensive ethical frameworks for human augmentation technologies, ensuring that the enhancement of human capabilities respects fundamental human rights, promotes individual autonomy, maintains human dignity, and advances social justice.

### 1.2 Scope

The standard covers:
- Ethical principles for augmentation design and deployment
- Informed consent frameworks and protocols
- Distinction between therapeutic and enhancement augmentation
- Equity, access, and justice considerations
- Prevention of coercion and undue influence
- Preservation of personal identity and authenticity
- Reversibility standards and requirements
- Special protections for vulnerable populations
- Societal impact assessment

### 1.3 Philosophy

**弘益人間 (Benefit All Humanity)** - Human augmentation should enhance human flourishing while respecting the inherent dignity, autonomy, and equality of all persons. Technology must serve humanity, not diminish it.

### 1.4 Terminology

- **Augmentation**: Technology that enhances human physical or cognitive capabilities
- **Therapeutic**: Treatment of disease or disability to restore normal function
- **Enhancement**: Improvement beyond species-typical functioning
- **Autonomy**: Capacity for self-determination and informed decision-making
- **Coercion**: Pressure that compromises voluntary decision-making
- **Vulnerable Population**: Groups requiring special ethical protections
- **Reversibility**: Ability to restore pre-augmentation state

---

## 2. Ethical Principles Framework

### 2.1 Six Core Ethical Principles

All human augmentation must be evaluated against six fundamental ethical principles:

#### 2.1.1 Autonomy

**Definition**: Respect for individual self-determination and decision-making capacity.

**Requirements**:
- Informed consent must be obtained
- Freedom from coercion or undue influence
- Right to accept or refuse augmentation
- Right to withdraw consent at any time
- Cultural and religious values respected

**Assessment Criteria**:
```
Autonomy Score = (Information × Comprehension × Voluntariness × Capacity) / 4

Where each factor is rated 0-10:
- Information: Completeness of disclosure
- Comprehension: Subject's understanding
- Voluntariness: Freedom from coercion
- Capacity: Decision-making ability
```

**Thresholds**:
- Score ≥ 8.0: Autonomy satisfied
- Score 6.0-7.9: Concerns requiring mitigation
- Score < 6.0: Autonomy not satisfied

#### 2.1.2 Beneficence

**Definition**: Actions must promote the well-being and best interests of the individual.

**Requirements**:
- Expected benefits must be significant
- Benefits must outweigh risks
- Quality of life improvement demonstrated
- Subject's own values and goals considered
- Long-term benefits evaluated

**Benefit Categories**:
1. Medical/Therapeutic: Improved health, function restoration
2. Functional: Enhanced capabilities, productivity
3. Psychological: Increased well-being, self-efficacy
4. Social: Improved relationships, opportunities

**Assessment**:
```
Beneficence Score = Σ(Benefit_i × Weight_i) - Risk_Burden

Where:
- Benefits are weighted by importance to subject
- Risk burden includes physical, psychological, social costs
```

#### 2.1.3 Non-Maleficence

**Definition**: "First, do no harm" - Obligation to avoid causing harm.

**Requirements**:
- Risks minimized to lowest feasible level
- Safety standards met (WIA-AUG-013)
- Harm prevention protocols in place
- Emergency procedures established
- Long-term safety monitored

**Harm Categories**:
1. Physical: Injury, disease, disability
2. Psychological: Mental distress, identity disruption
3. Social: Stigma, discrimination, isolation
4. Economic: Financial burden, employment impact

**Risk-Benefit Analysis**:
```
Acceptable Risk = (Expected Benefits / Potential Harms) ≥ Threshold

Thresholds by Augmentation Type:
- Therapeutic: 1.5
- Restorative: 2.0
- Enhancement: 3.0
- Experimental: 5.0
```

#### 2.1.4 Justice

**Definition**: Fair and equitable treatment, distribution, and access.

**Requirements**:
- No discrimination based on protected characteristics
- Fair selection criteria for access
- Equitable distribution of benefits and burdens
- Consideration of social determinants
- Remediation of existing inequities

**Justice Dimensions**:

**Distributive Justice**:
```
Access_Equity = (Actual_Access / Population_Need) across demographic groups

Target: Variance < 0.15 across groups
```

**Procedural Justice**:
- Fair decision-making processes
- Transparency in selection criteria
- Right to appeal decisions
- Stakeholder participation

**Compensatory Justice**:
- Priority for disadvantaged groups
- Subsidized access programs
- Accommodation for disabilities
- Remediation of past injustices

#### 2.1.5 Dignity

**Definition**: Respect for inherent human worth and inviolability.

**Requirements**:
- Human worth not contingent on capabilities
- Protection from degradation or objectification
- Respect for human embodiment
- Cultural and personal values honored
- Rights and personhood maintained

**Dignity Threats**:
1. Commodification: Treating persons as products
2. Instrumentalization: Using persons as means only
3. Dehumanization: Denying human status
4. Objectification: Reducing to functional capabilities

**Dignity Assessment**:
```
Questions to evaluate:
- Does augmentation respect human embodiment?
- Is person valued beyond augmented capabilities?
- Are human rights and personhood maintained?
- Is cultural/religious identity respected?
- Is there protection from degradation?
```

#### 2.1.6 Authenticity

**Definition**: Preservation of personal identity and genuine self.

**Requirements**:
- Changes aligned with person's values and goals
- Core identity elements preserved
- Narrative continuity maintained
- Alienation from self prevented
- Reversibility available when feasible

**Identity Dimensions**:
1. Psychological: Memories, personality, consciousness
2. Physical: Embodiment, sensorimotor experience
3. Narrative: Life story, personal history
4. Social: Relationships, roles, community
5. Values: Beliefs, commitments, goals

**Authenticity Assessment**:
```
Identity_Impact = Σ(Change_i × Centrality_i)

Where:
- Change: Degree of alteration (0-10)
- Centrality: Importance to core identity (0-10)

Thresholds:
- Impact < 25: Minimal identity change
- Impact 25-50: Moderate change, monitoring required
- Impact > 50: Substantial change, enhanced consent required
```

### 2.2 Principle Integration

All six principles must be satisfied for ethical compliance:

```typescript
interface EthicalAssessment {
  principleScores: {
    autonomy: number;
    beneficence: number;
    nonMaleficence: number;
    justice: number;
    dignity: number;
    authenticity: number;
  };

  overallCompliance: boolean;
  concerns: string[];
  recommendations: string[];
}

function assessCompliance(scores: PrincipleScores): boolean {
  return Object.values(scores).every(score => score >= THRESHOLD);
}
```

**Compliance Requirements**:
- All six principles score ≥ 7.0/10
- No principle scores < 5.0/10
- Overall average ≥ 8.0/10
- All critical concerns addressed

---

## 3. Informed Consent Protocols

### 3.1 Consent Level Framework

Four levels of informed consent based on augmentation type:

| Level | Type | Requirements | Duration |
|-------|------|-------------|----------|
| **BASIC** | Therapeutic | Standard medical consent | Single session |
| **ENHANCED** | Restorative | Detailed risks/benefits | Multiple sessions |
| **COMPREHENSIVE** | Enhancement | Full long-term implications | Extended process |
| **EXPERIMENTAL** | Experimental | Complete uncertainty disclosure | Ongoing |

### 3.2 Basic Consent (Therapeutic Augmentation)

**Applies to**: Medically necessary augmentation for disease/disability treatment

**Required Elements**:
1. Nature and purpose of augmentation
2. Expected benefits
3. Material risks and complications
4. Available alternatives
5. Right to refuse
6. Opportunity to ask questions

**Process**:
```
1. Information disclosure (written + verbal)
2. Comprehension assessment
3. Voluntary agreement
4. Documentation and signature
5. Cooling-off period (24 hours minimum)
```

### 3.3 Enhanced Consent (Restorative Augmentation)

**Applies to**: Restoration of normal function through augmentation

**Additional Requirements**:
- Detailed risk-benefit analysis
- Long-term maintenance requirements
- Lifestyle impact assessment
- Financial obligations
- Success rate statistics
- Failure scenarios and contingencies

**Process**:
```
Session 1: Initial information and assessment
Session 2: Detailed discussion of risks and benefits (72 hours later)
Session 3: Final consent and documentation (1 week later)
```

### 3.4 Comprehensive Consent (Enhancement Augmentation)

**Applies to**: Augmentation beyond normal capabilities

**Additional Requirements**:
- Philosophical and ethical implications
- Identity and authenticity impacts
- Social and occupational consequences
- Societal implications
- Reversibility options and limitations
- Long-term unknown risks
- Enhancement alternatives (training, tools)

**Process**:
```
Phase 1: Education (multiple sessions over 2+ weeks)
Phase 2: Psychological assessment
Phase 3: Ethics committee review
Phase 4: Trial period (if applicable)
Phase 5: Final comprehensive consent
Phase 6: Cooling-off period (30 days minimum)
```

**Documentation Requirements**:
```json
{
  "consentType": "COMPREHENSIVE",
  "subject": {
    "id": "anonymized",
    "age": 0,
    "capacityAssessment": "documented",
    "psychologicalEvaluation": "completed"
  },
  "augmentation": {
    "type": "enhancement",
    "category": "cognitive|physical|sensory",
    "description": "detailed",
    "reversibility": "score 0-1"
  },
  "disclosures": {
    "risks": ["comprehensive list"],
    "benefits": ["detailed benefits"],
    "alternatives": ["non-augmentation options"],
    "unknowns": ["long-term uncertainties"],
    "identity": ["potential impacts"],
    "social": ["societal implications"]
  },
  "sessions": [
    {
      "date": "ISO-8601",
      "topics": ["covered"],
      "comprehension": "verified",
      "questions": ["addressed"]
    }
  ],
  "signatures": {
    "subject": "signed with date",
    "witness": "independent witness",
    "ethicsOfficer": "ethics approval",
    "physician": "medical clearance"
  }
}
```

### 3.5 Experimental Consent

**Applies to**: Unproven or research-stage augmentation

**Additional Requirements**:
- Explicit acknowledgment of experimental nature
- Complete disclosure of uncertainties
- No guarantee of benefits
- Potential for unforeseen consequences
- Right to withdraw at any time
- Compensation for research injuries
- Independent oversight (IRB/Ethics Board)

**Special Provisions**:
- Ongoing consent (periodic renewal)
- Enhanced monitoring and reporting
- Immediate notification of new risks
- Community consultation (if applicable)
- Public registry of experimental augmentations

### 3.6 Capacity Assessment

All consent requires verified decision-making capacity:

```
Capacity Criteria:
1. Understanding: Comprehends information
2. Appreciation: Recognizes personal relevance
3. Reasoning: Weighs risks and benefits rationally
4. Expression: Communicates clear choice

Assessment Methods:
- Standardized capacity instruments
- Clinical evaluation by qualified professional
- Documentation of assessment results
- Periodic reassessment for experimental consent
```

**Incapacity Protocols**:
- Surrogate decision-makers (therapeutic only)
- Best interest standards
- Advance directives honored
- Legal guardianship requirements
- No enhancement for incapacitated persons

### 3.7 Consent Documentation

All consent must be documented with:

```
Required Documentation:
□ Consent form (signed and dated)
□ Information disclosure record
□ Comprehension assessment results
□ Capacity evaluation
□ Questions and answers log
□ Witness attestation (for enhanced/comprehensive)
□ Ethics committee approval (for comprehensive/experimental)
□ Cooling-off period confirmation
□ Right to withdraw notification
```

---

## 4. Enhancement vs Therapy Distinction

### 4.1 Classification Framework

Clear distinction between therapeutic and enhancement augmentation:

```
THERAPEUTIC:
- Treats disease or pathology
- Restores to normal functioning
- Medically indicated
- Standard medical ethics apply

RESTORATIVE:
- Repairs injury or deficit
- Returns to baseline capabilities
- Medically beneficial
- Enhanced disclosure required

ENHANCEMENT:
- Exceeds normal capabilities
- Improves beyond species-typical
- Elective choice
- Comprehensive ethics review required

EXPERIMENTAL:
- Unproven technology
- Research purposes
- Uncertain outcomes
- Full research ethics protocols
```

### 4.2 Classification Algorithm

```typescript
enum AugmentationType {
  THERAPEUTIC = 'THERAPEUTIC',
  RESTORATIVE = 'RESTORATIVE',
  ENHANCEMENT = 'ENHANCEMENT',
  EXPERIMENTAL = 'EXPERIMENTAL'
}

interface ClassificationInput {
  currentFunction: number;      // 0-100, population baseline = 50
  targetFunction: number;        // 0-100
  medicalNecessity: boolean;
  pathologyPresent: boolean;
  provenEffective: boolean;
}

function classifyAugmentation(input: ClassificationInput): AugmentationType {
  // Experimental if unproven
  if (!input.provenEffective) {
    return AugmentationType.EXPERIMENTAL;
  }

  // Therapeutic if treating pathology
  if (input.pathologyPresent && input.medicalNecessity) {
    return AugmentationType.THERAPEUTIC;
  }

  // Restorative if returning to baseline
  if (input.currentFunction < 50 && input.targetFunction <= 50) {
    return AugmentationType.RESTORATIVE;
  }

  // Enhancement if exceeding normal
  if (input.targetFunction > 50) {
    return AugmentationType.ENHANCEMENT;
  }

  return AugmentationType.RESTORATIVE;
}
```

### 4.3 Ethical Implications by Type

#### Therapeutic Augmentation
- Standard medical ethics
- Insurance coverage appropriate
- Physician discretion primary
- Basic informed consent sufficient
- Public health priority

#### Restorative Augmentation
- Enhanced ethical review
- Insurance consideration warranted
- Shared decision-making
- Enhanced informed consent
- Individual and social benefits

#### Enhancement Augmentation
- Comprehensive ethical review
- Private payment expected
- Individual autonomy primary
- Comprehensive informed consent
- Equity concerns heightened
- Identity impacts significant
- Societal implications major

#### Experimental Augmentation
- Research ethics protocols
- IRB/Ethics board required
- Compensation for participation
- Experimental consent
- Maximum oversight
- Public interest high
- Unknown risk profile

### 4.4 Gray Areas

Some augmentation defies clear classification:

**Example: Cognitive Enhancement for Age-Related Decline**
- Therapeutic? (treating aging as disease)
- Restorative? (returning to younger baseline)
- Enhancement? (exceeding current normal aging)

**Resolution Framework**:
1. Apply most stringent ethical requirements
2. Seek ethics committee guidance
3. Document rationale clearly
4. Apply comprehensive consent
5. Monitor outcomes carefully

---

## 5. Equity and Access Considerations

### 5.1 Justice Framework

Augmentation must not exacerbate existing inequities:

**Distributive Justice Principles**:
1. Equal access to therapeutic augmentation
2. Fair allocation of scarce resources
3. Priority to medical need over enhancement
4. Consideration of social determinants
5. Remediation of structural inequities

### 5.2 Access Barriers

Identified barriers requiring mitigation:

#### Economic Barriers
```
Cost Assessment:
- Procedure cost
- Maintenance/upgrades
- Time off work
- Travel and accommodations
- Lost opportunity costs

Mitigation:
- Sliding scale pricing
- Payment plans
- Charitable funding
- Public subsidies (therapeutic)
- Insurance coverage mandates
```

#### Geographic Barriers
- Rural/remote access
- Provider concentration in urban areas
- Travel requirements
- Telemedicine options

#### Social Barriers
- Stigma and discrimination
- Cultural appropriateness
- Language access
- Health literacy
- Trust in medical system

#### Systemic Barriers
- Insurance coverage gaps
- Regulatory restrictions
- Provider biases
- Institutional discrimination

### 5.3 Equity Assessment

```typescript
interface EquityAssessment {
  accessBarriers: {
    economic: number;      // 0-10
    geographic: number;
    social: number;
    systemic: number;
  };

  demographicDistribution: {
    income: DistributionMetric;
    race: DistributionMetric;
    geography: DistributionMetric;
    disability: DistributionMetric;
  };

  equityScore: number;      // 0-100
  concerns: string[];
  mitigations: string[];
}

interface DistributionMetric {
  giniCoefficient: number;  // 0 = perfect equality, 1 = perfect inequality
  representationRatio: number; // Actual / Expected distribution
}

// Equity score calculation
EquityScore = 100 - (Σ(Barrier_i × Weight_i) + Σ(Inequality_j × Weight_j))

// Thresholds:
// Score ≥ 80: Equitable access
// Score 60-79: Concerns, mitigation required
// Score < 60: Inequitable, major intervention needed
```

### 5.4 Equity Requirements

**Therapeutic Augmentation**:
- Universal access mandate
- Public health priority
- Insurance coverage required
- Sliding scale for uninsured
- Outreach to underserved

**Restorative Augmentation**:
- Broad access encouraged
- Insurance consideration
- Subsidies for low-income
- Anti-discrimination protections

**Enhancement Augmentation**:
- Market allocation acceptable
- Anti-discrimination laws apply
- Monitor for inequity
- Prevent coercive advantage
- Public education on risks

### 5.5 Enhancement Divide Prevention

**Concerns**:
- Widening gap between enhanced and non-enhanced
- Creation of genetic/augmentation aristocracy
- Entrenched social stratification
- Decreased social mobility
- Discrimination against non-enhanced

**Safeguards**:
```
1. Anti-discrimination laws
   - Prohibit enhancement-based discrimination
   - Protect non-enhanced individuals
   - Mandate reasonable accommodations

2. Enhancement-neutral opportunities
   - Education accessible to all
   - Employment based on competence
   - Merit not contingent on enhancement

3. Social safety net
   - Universal basic services
   - Healthcare access for all
   - Economic opportunity regardless of enhancement

4. Monitoring and regulation
   - Track enhancement distribution
   - Assess social impact
   - Intervene if inequity emerges
   - Adjust policy as needed
```

---

## 6. Coercion Prevention

### 6.1 Coercion Definition

**Coercion**: Pressure that compromises voluntary decision-making through threats, force, or manipulation.

**Forms of Coercion**:
1. Direct: Explicit threats or force
2. Indirect: Structural pressures or incentives
3. Subtle: Social pressure or manipulation
4. Internalized: Self-imposed from societal norms

### 6.2 Coercion Risk Factors

```typescript
interface CoercionRisk {
  context: 'occupational' | 'military' | 'educational' | 'social' | 'familial';

  indicators: {
    mandatoryRequirement: boolean;
    employmentConsequence: boolean;
    peerPressure: boolean;
    authorityPressure: boolean;
    financialIncentive: boolean;
    limitedAlternatives: boolean;
    powerImbalance: boolean;
    timeConstraint: boolean;
  };

  riskLevel: 'none' | 'low' | 'moderate' | 'high' | 'severe';
}

// Risk calculation
CoercionRisk = Σ(Indicator_i × Weight_i) × ContextMultiplier

Thresholds:
- None: Score 0-1
- Low: Score 2-4
- Moderate: Score 5-7
- High: Score 8-10
- Severe: Score > 10 (immediate intervention)
```

### 6.3 Prohibited Coercive Practices

**Absolutely Prohibited**:
1. Mandatory augmentation for employment (with exceptions*)
2. Augmentation as prerequisite for education
3. Financial penalties for non-augmentation
4. Denial of services based on augmentation status
5. Manipulation through misinformation
6. Exploitation of vulnerability

*Exceptions: Highly specific occupational requirements with no reasonable alternative (case-by-case ethics review required)

### 6.4 Occupational Context

**Ethical Framework**:
```
Question 1: Is augmentation genuinely necessary for job function?
  → If No: Prohibited

Question 2: Are reasonable accommodations available?
  → If Yes: Accommodation required, augmentation optional

Question 3: Is augmentation narrowly tailored to specific need?
  → If No: Overly broad, prohibited

Question 4: Are alternatives available (tools, training, reassignment)?
  → If Yes: Alternatives must be offered

Question 5: Is there independent ethics review?
  → If No: Cannot proceed
```

**Permitted Occupational Requirements** (with safeguards):
- Specific sensory augmentation for safety-critical roles
- Narrow therapeutic augmentation for medical fitness
- Time-limited enhancement with full consent
- Employer-funded with no cost to employee
- Removal/reversal upon job separation
- Alternative positions available

**Prohibited Occupational Requirements**:
- General enhancement for productivity
- Cosmetic augmentation for customer service
- Monitoring/surveillance implants
- Augmentation transferring risk from employer to employee
- Enhancement as substitute for training or tools

### 6.5 Military Context

**Special Considerations**:
- Chain of command creates inherent coercion risk
- National security interests vs. individual rights
- Voluntariness difficult in military hierarchy
- Long-term consequences for veterans

**Ethical Requirements**:
```
1. Voluntary augmentation only
   - Explicit opt-in required
   - No career consequences for refusal
   - Alternative assignments available

2. Enhanced informed consent
   - Independent counseling
   - Extended cooling-off period
   - Right to withdraw consent

3. Service member protections
   - Full medical support
   - Removal upon discharge
   - VA coverage for complications
   - Disability benefits if harmed

4. Civilian ethics oversight
   - Independent ethics board
   - External review of programs
   - Public transparency

5. Reversibility priority
   - Maximum reversibility required
   - Removal protocols established
   - Long-term monitoring
```

### 6.6 Educational Context

**Prohibited**:
- Augmentation as admission requirement
- Enhancement for academic performance
- Pressure from educational institutions

**Permitted** (with safeguards):
- Therapeutic augmentation for disabilities (voluntary)
- Accommodations without augmentation
- Student autonomy in all decisions

### 6.7 Coercion Detection and Intervention

```typescript
function detectCoercion(context: Context): CoercionAssessment {
  const indicators = assessIndicators(context);
  const riskLevel = calculateRisk(indicators);

  if (riskLevel >= 'moderate') {
    return {
      coercionDetected: true,
      interventionsRequired: [
        'Independent counseling',
        'Extended cooling-off period',
        'Alternative options required',
        'Ethics committee review',
        'External advocacy'
      ]
    };
  }
}

// Intervention escalation
Moderate Risk → Enhanced consent + counseling
High Risk → Ethics review + alternative required
Severe Risk → Halt augmentation + investigation
```

---

## 7. Identity and Authenticity Preservation

### 7.1 Personal Identity Framework

Human augmentation can impact multiple dimensions of personal identity:

```typescript
interface IdentityDimensions {
  psychological: {
    memory: number;          // Impact on memories (0-10)
    personality: number;     // Changes to personality traits
    consciousness: number;   // Alterations to subjective experience
    emotions: number;        // Effects on emotional life
  };

  physical: {
    embodiment: number;      // Changes to bodily experience
    appearance: number;      // Visible physical changes
    capabilities: number;    // Functional changes
    sensorimotor: number;    // Perceptual/motor changes
  };

  narrative: {
    continuity: number;      // Disruption to life story
    meaning: number;         // Changes to life meaning
    autobiography: number;   // Alterations to personal history
  };

  social: {
    relationships: number;   // Impact on relationships
    roles: number;           // Changes to social roles
    community: number;       // Effects on community belonging
    identity: number;        // Social identity changes
  };

  values: {
    beliefs: number;         // Changes to core beliefs
    commitments: number;     // Shifts in commitments
    goals: number;           // Alterations to life goals
    worldview: number;       // Changes to worldview
  };
}
```

### 7.2 Identity Impact Assessment

```
IdentityImpact = Σ(Dimension_i × Centrality_i × Magnitude_i)

Where:
- Dimension: Psychological, Physical, Narrative, Social, Values
- Centrality: Importance to core identity (1-10)
- Magnitude: Degree of change (0-10)

Interpretation:
- Impact 0-25: Minimal (standard consent)
- Impact 26-50: Moderate (enhanced consent, monitoring)
- Impact 51-75: Substantial (comprehensive consent, support)
- Impact 76-100: Severe (may be unethical, extensive review required)
```

### 7.3 Authenticity Criteria

Augmentation respects authenticity when:

1. **Value Alignment**: Changes align with person's core values and goals
2. **Narrative Coherence**: Life story remains comprehensible and meaningful
3. **Psychological Continuity**: Connection to past self maintained
4. **Relational Identity**: Key relationships sustained
5. **Self-Recognition**: Person recognizes self in augmented state

**Assessment Questions**:
```
□ Does augmentation reflect subject's authentic goals?
□ Is change continuous with personal history?
□ Does person identify with augmented capabilities?
□ Are core values and commitments preserved?
□ Do important others still recognize person?
□ Can person narrate coherent life story?
□ Is augmentation chosen, not imposed?
□ Does person feel "like themselves"?
```

### 7.4 Identity Disruption Risks

**High-Risk Augmentations**:
- Cognitive enhancements affecting personality
- Memory modification or enhancement
- Emotion regulation implants
- Radical appearance alterations
- Consciousness-altering technologies
- Value-influencing interventions

**Risk Mitigation**:
```
1. Gradual implementation
   - Incremental changes over time
   - Adaptation periods between stages
   - Monitoring of identity impacts

2. Reversibility options
   - Removal or deactivation possible
   - Return to baseline capabilities
   - Identity preservation priority

3. Psychological support
   - Pre-augmentation counseling
   - Ongoing identity therapy
   - Support for adaptation
   - Crisis intervention available

4. Social support
   - Peer support groups
   - Family involvement (with consent)
   - Community resources

5. Monitoring and intervention
   - Regular identity assessments
   - Early detection of disruption
   - Intervention if severe impact
   - Option to reverse/modify
```

### 7.5 Self-Alienation Prevention

**Self-Alienation**: Feeling disconnected from augmented self or capabilities.

**Warning Signs**:
- "This isn't really me"
- Disowning augmented capabilities
- Distress about identity changes
- Loss of narrative coherence
- Relationship disruptions
- Feeling like "a different person"

**Interventions**:
```
1. Identity integration therapy
2. Narrative reconstruction
3. Gradual adjustment of augmentation
4. Consideration of reversal
5. Peer support connection
6. Meaning-making facilitation
```

### 7.6 Enhancement and Character

**Ethical Concern**: Does enhancement undermine character development?

**Considerations**:
- Value of effort and struggle in human flourishing
- Meaning of accomplishment with vs. without enhancement
- Development of virtues through challenge
- Authentic achievement and self-worth
- "Shortcut" vs. "earned" capabilities

**Framework**:
```
Character preservation requires:
1. Enhancement aligned with person's developmental goals
2. Continued opportunity for meaningful challenge
3. Recognition of effort (enhanced and non-enhanced)
4. Value not contingent solely on capabilities
5. Character virtues cultivatable with augmentation
```

---

## 8. Reversibility Requirements

### 8.1 Reversibility Principle

**Principle**: Augmentation should be reversible unless irreversibility is justified by substantial benefit and explicitly consented to.

**Rationale**:
- Respects autonomy (can change mind)
- Mitigates identity risks
- Reduces coercion concerns
- Allows adaptation and adjustment
- Protects against unforeseen consequences

### 8.2 Reversibility Classification

```typescript
enum ReversibilityLevel {
  FULLY_REVERSIBLE = 'FULLY_REVERSIBLE',      // 90-100% restoration
  LARGELY_REVERSIBLE = 'LARGELY_REVERSIBLE',   // 70-89% restoration
  PARTIALLY_REVERSIBLE = 'PARTIALLY_REVERSIBLE', // 40-69% restoration
  MINIMALLY_REVERSIBLE = 'MINIMALLY_REVERSIBLE', // 10-39% restoration
  IRREVERSIBLE = 'IRREVERSIBLE'                // 0-9% restoration
}

interface ReversibilityProfile {
  level: ReversibilityLevel;
  restorationPercentage: number;  // 0-100
  reversalProcess: {
    surgical: boolean;
    duration: number;              // days
    risk: 'low' | 'moderate' | 'high';
    cost: number;
  };
  permanentChanges: string[];
  recovery: {
    physical: number;              // days
    psychological: number;         // days
    functional: number;            // days
  };
}
```

### 8.3 Reversibility Requirements by Augmentation Type

#### Therapeutic Augmentation
- Reversibility encouraged but not required
- Medical necessity may justify irreversibility
- Risk-benefit analysis determines requirements
- Enhanced consent for irreversible procedures

#### Restorative Augmentation
- Reversibility highly encouraged
- Irreversibility requires justification
- Alternative reversible options explored
- Detailed disclosure of permanent changes

#### Enhancement Augmentation
- **Reversibility strongly preferred**
- Irreversible enhancement requires:
  - Compelling justification
  - Comprehensive consent
  - Ethics committee approval
  - Extended cooling-off period
  - Psychological assessment
  - Trial of reversible alternatives

#### Experimental Augmentation
- **Maximum reversibility required**
- Irreversible experiments prohibited except:
  - Therapeutic necessity
  - No reversible alternative
  - IRB approval
  - Extraordinary consent process

### 8.4 Reversibility Assessment

```
Reversibility Score = (Physical × 0.4) + (Functional × 0.3) + (Identity × 0.3)

Where each component (0-100):

Physical Reversibility:
- Percentage of anatomical restoration
- Removal of implanted components
- Healing of surgical modifications

Functional Reversibility:
- Recovery of pre-augmentation capabilities
- Restoration of normal function
- Absence of permanent deficits

Identity Reversibility:
- Return to pre-augmentation sense of self
- Reversal of identity impacts
- Restoration of psychological continuity

Thresholds:
- ≥90: Fully reversible
- 70-89: Largely reversible
- 40-69: Partially reversible
- 10-39: Minimally reversible
- <10: Irreversible
```

### 8.5 Justifications for Irreversibility

Irreversible augmentation may be ethically acceptable when:

1. **Medical Necessity**: Therapeutic benefit requires irreversibility
2. **Technical Impossibility**: Reversibility not technologically feasible
3. **Proportionate Benefit**: Benefits vastly outweigh reversibility loss
4. **Subject Preference**: Informed subject explicitly chooses irreversibility
5. **Risk Reduction**: Reversibility would increase overall risk

**Required Documentation**:
```json
{
  "justification": "medical_necessity",
  "rationale": "Detailed explanation of why irreversibility is required",
  "alternatives": {
    "reversibleOptions": ["List of reversible alternatives considered"],
    "whyNotFeasible": ["Explanation of why alternatives inadequate"]
  },
  "consent": {
    "type": "COMPREHENSIVE",
    "irreversibilityDisclosed": true,
    "subjectAcknowledgment": "Signed statement understanding irreversibility",
    "coolingOffPeriod": "30 days minimum",
    "psychologicalAssessment": "Completed",
    "ethicsApproval": "Committee approval reference"
  }
}
```

### 8.6 Reversal Protocols

For reversible augmentations, clear reversal protocols required:

```
Reversal Protocol Components:
1. Eligibility criteria for reversal
2. Reversal process description
3. Timeline and stages
4. Expected outcomes and limitations
5. Risks and complications
6. Recovery and rehabilitation
7. Support services
8. Cost and coverage
9. Follow-up care

Reversal Rights:
- Right to request reversal at any time
- No penalty for requesting reversal
- Support for reversal decision
- Financial arrangements clear upfront
- Access to reversal regardless of ability to pay (therapeutic)
```

### 8.7 Partial Reversibility Management

When full reversibility impossible, requirements include:

```
1. Clear disclosure
   - Specific permanent changes identified
   - Percentage reversibility quantified
   - Limitations explicitly described

2. Staged approach
   - Maximize reversible options first
   - Delay irreversible components
   - Trial periods before permanence

3. Enhanced consent
   - Multiple sessions
   - Independent review
   - Psychological assessment
   - Extended cooling-off period

4. Ongoing support
   - Long-term monitoring
   - Adaptation assistance
   - Intervention if needed
```

---

## 9. Vulnerable Population Protections

### 9.1 Vulnerable Populations Defined

Groups requiring special ethical protections:

1. **Children and Adolescents**
2. **Individuals with Cognitive Impairments**
3. **Economically Disadvantaged**
4. **Institutionalized Persons**
5. **Ethnic and Racial Minorities** (historical discrimination)
6. **Military Personnel** (context-dependent)
7. **Prisoners**
8. **Refugees and Displaced Persons**

### 9.2 Children and Adolescents

**General Principle**: **Therapeutic only** until age of majority.

#### 9.2.1 Therapeutic Augmentation in Children

**Permitted when**:
- Medically necessary
- Cannot safely wait until adulthood
- Expected benefit substantial
- Risks proportionate
- Best interest of child

**Requirements**:
```
1. Parental/Guardian consent
2. Child assent (if capable)
3. Independent medical evaluation
4. Ethics committee review
5. Least invasive option
6. Maximum reversibility
7. Delayed timing if possible
8. Child's future autonomy preserved
```

#### 9.2.2 Enhancement Augmentation in Children

**General Prohibition**: Enhancement of children prohibited.

**Rationale**:
- Cannot provide informed consent
- Identity still developing
- Cannot appreciate long-term implications
- Risk of parental coercion
- Permanent alteration of developing person
- Violates child's future autonomy

**Absolute Prohibitions**:
- Cognitive enhancement
- Cosmetic enhancement
- Performance enhancement (academic, athletic)
- Social enhancement
- Any irreversible enhancement

**Possible Exception** (case-by-case, extraordinary circumstances):
- Immediate and severe harm without enhancement
- No therapeutic alternative
- Independent advocacy for child
- Judicial review
- Maximum reversibility required
- Deferred until adolescence if possible

#### 9.2.3 Adolescent Augmentation

**Ages 16-18**: Transitional framework

```
Therapeutic:
- Standard pediatric protections
- Increasing weight to adolescent assent
- Preparation for adult decision-making

Restorative:
- May be considered case-by-case
- Ethics review required
- Adolescent assent essential
- Parental consent still required
- Prefer to delay until 18 if safe

Enhancement:
- Generally prohibited
- Extraordinary circumstances only
- Judicial review
- Independent advocacy
- Maximum protections
```

### 9.3 Cognitive Impairment

**Principle**: Therapeutic only, best interest standard, surrogate consent with safeguards.

#### 9.3.1 Decision-Making Capacity Assessment

```
Capacity Domains:
1. Understanding: Comprehends information
2. Appreciation: Recognizes personal relevance
3. Reasoning: Weighs options rationally
4. Expression: Communicates choice

Assessment:
- Standardized instruments
- Qualified evaluator
- Domain-specific (may have partial capacity)
- Periodic reassessment
- Documentation required
```

#### 9.3.2 Surrogate Decision-Making

**When capacity lacking**:

```
Surrogate Decision-Maker Selection:
1. Legal guardian (if appointed)
2. Healthcare proxy (if designated)
3. Family member (spouse, adult child, parent, sibling)
4. Close friend (if no family)
5. Public guardian (last resort)

Surrogate Standards:
1. Substituted judgment: What would person want?
2. Best interest: What serves person's well-being?

Requirements:
- Surrogate acts in person's best interest
- Person's known preferences considered
- Least restrictive alternative
- Preserves person's dignity
- Independent oversight
```

#### 9.3.3 Protections for Cognitively Impaired

```
1. Therapeutic priority
   - Enhancement prohibited
   - Medical necessity required
   - Improvement in function/well-being

2. Reversibility maximum
   - Fully reversible strongly preferred
   - Irreversibility requires extraordinary justification

3. Independent advocacy
   - Separate from surrogate
   - Represents person's interests
   - Can object to augmentation

4. Ethics committee review
   - All cases reviewed
   - Particular scrutiny for irreversible
   - Community representation

5. Judicial review
   - For contested cases
   - Irreversible augmentation
   - Substantial identity impact

6. Ongoing monitoring
   - Regular assessment
   - Early intervention
   - Right to discontinue
```

### 9.4 Economically Disadvantaged

**Concerns**:
- Exploitation through financial incentives
- Undue inducement to participate in experiments
- Pressure to augment for employment
- Inability to afford complications/maintenance
- Systematic exclusion from beneficial augmentation

**Protections**:

```
1. Fair compensation
   - Research: Reasonable compensation, not undue inducement
   - Employment: No cost to individual for job-required augmentation

2. Access programs
   - Sliding scale pricing
   - Charitable funding
   - Public subsidies (therapeutic)
   - Insurance mandates

3. Anti-exploitation measures
   - Independent oversight
   - Screening for economic coercion
   - Alternative options required
   - Right to withdraw without penalty

4. Long-term support
   - Maintenance coverage
   - Upgrade access
   - Complication treatment
   - Reversal funding
```

### 9.5 Institutionalized Persons

**Principle**: Highest scrutiny, therapeutic only, strong presumption against augmentation.

#### 9.5.1 Prisoners

```
Permitted:
- Medically necessary therapeutic augmentation
- Standard medical care

Prohibited:
- Enhancement augmentation
- Experimental augmentation (unless directly therapeutic)
- Behavior modification implants
- Augmentation as condition of release
- Monitoring/surveillance devices

Requirements (if therapeutic):
- Independent medical necessity determination
- Separate from correctional authority
- Enhanced informed consent
- External ethics review
- Judicial oversight
- Community standard of care
```

#### 9.5.2 Psychiatric Institutions

```
Protections:
- Capacity assessment required
- Voluntary admission vs. involuntary (higher scrutiny)
- No coercion from institution
- Independent advocacy
- Right to refuse
- Periodic review
- Court approval (for involuntary patients)

Prohibited:
- Involuntary enhancement
- Augmentation for institutional convenience
- Experimental augmentation (generally)
```

### 9.6 Ethnic and Racial Minorities

**Historical Context**: Medical experimentation and exploitation.

**Protections**:

```
1. Trust building
   - Community engagement
   - Representation in research
   - Transparency in processes
   - Accountability mechanisms

2. Cultural sensitivity
   - Culturally appropriate consent
   - Language access
   - Cultural values respected
   - Community input

3. Anti-discrimination
   - Equal access to therapeutic augmentation
   - No targeting for experiments
   - Fair distribution of benefits
   - Monitoring for disparities

4. Community oversight
   - Community advisory boards
   - Meaningful participation
   - Veto power over research
   - Benefit sharing
```

### 9.7 Refugees and Displaced Persons

```
Concerns:
- Vulnerability to exploitation
- Pressure to augment for employment/asylum
- Limited alternatives
- Language and cultural barriers
- Lack of long-term support

Protections:
- Enhanced consent (language appropriate)
- Independent advocacy
- No augmentation linked to asylum/status
- Long-term support commitments
- Cultural sensitivity
- Community involvement
```

### 9.8 General Vulnerable Population Principles

```
1. Therapeutic priority: Enhancement generally prohibited
2. Maximum reversibility: Irreversibility requires extraordinary justification
3. Enhanced consent: Additional protections and oversight
4. Independent advocacy: Separate from interested parties
5. Ethics review: Mandatory for all cases
6. Judicial oversight: For high-risk or contested cases
7. Community involvement: Representation and input
8. Long-term support: Commitment beyond procedure
9. Right to withdraw: Can discontinue without penalty
10. Regular monitoring: Ongoing assessment and intervention
```

---

## 10. Implementation Guidelines

### 10.1 Ethical Review Structure

#### 10.1.1 Ethics Committee Composition

```
Required Members:
- Bioethicist (chair)
- Physician (augmentation specialist)
- Psychologist/Psychiatrist
- Legal expert
- Community representative
- Patient advocate
- Ethicist (second)
- Technical expert (as needed)

Desired Diversity:
- Gender balance
- Racial/ethnic diversity
- Disability representation
- Range of perspectives
```

#### 10.1.2 Review Process

```
Standard Review (Therapeutic):
1. Application submission
2. Committee review (2-4 weeks)
3. Decision: Approve, Deny, Request Modifications
4. Appeal process available

Enhanced Review (Restorative/Enhancement):
1. Pre-application consultation
2. Full application submission
3. Committee review (4-8 weeks)
4. Subject interview (if needed)
5. Decision with detailed rationale
6. Appeal to higher ethics board

Expedited Review:
- Therapeutic necessity
- Time-sensitive
- Minimal risk
- Single reviewer + chair
- Full committee notification

Ongoing Review (Experimental):
- Initial approval
- Periodic progress reports
- Adverse event reporting
- Annual renewal
- Modification approval required
```

### 10.2 Certification Requirements

To achieve WIA-AUG-012 certification:

```
Required Elements:
□ Ethics committee established
□ Consent protocols implemented (all 4 levels)
□ Augmentation classification system
□ Equity assessment process
□ Coercion screening procedures
□ Identity impact assessment
□ Reversibility evaluation
□ Vulnerable population protections
□ Documentation system
□ Training program
□ Audit mechanism
□ Public transparency

Documentation:
□ Ethics policy manual
□ Consent form templates
□ Assessment instruments
□ Committee meeting minutes
□ Decisions and rationale
□ Adverse event reports
□ Annual compliance reports
```

### 10.3 API Interface

```typescript
// Core ethical assessment function
interface EthicalAssessmentRequest {
  augmentation: AugmentationDetails;
  subject: SubjectProfile;
  context: DecisionContext;
}

interface EthicalAssessmentResult {
  compliant: boolean;
  principlesSatisfied: EthicalPrinciple[];
  concerns: EthicalConcern[];
  recommendations: string[];
  requiredActions: RequiredAction[];
  approvalLevel: 'automatic' | 'standard' | 'enhanced' | 'prohibited';
}

function assessEthicalCompliance(
  request: EthicalAssessmentRequest
): EthicalAssessmentResult;

// Consent validation
interface ConsentValidationRequest {
  subjectId: string;
  augmentationType: AugmentationType;
  requiredLevel: ConsentLevel;
  providedConsent: ConsentDocumentation;
}

interface ConsentValidationResult {
  valid: boolean;
  gaps: string[];
  recommendations: string[];
}

function validateConsent(
  request: ConsentValidationRequest
): ConsentValidationResult;

// Coercion check
interface CoercionCheckRequest {
  context: CoercionContext;
  indicators: CoercionIndicator[];
}

interface CoercionCheckResult {
  coercionDetected: boolean;
  riskLevel: 'none' | 'low' | 'moderate' | 'high' | 'severe';
  concerns: string[];
  interventions: string[];
}

function checkCoercion(
  request: CoercionCheckRequest
): CoercionCheckResult;

// Additional functions
function evaluateEquity(context: EquityContext): EquityAssessment;
function assessIdentityImpact(augmentation: AugmentationDetails): IdentityImpact;
function reviewReversibility(augmentation: AugmentationDetails): ReversibilityProfile;
function protectVulnerable(subject: SubjectProfile): VulnerableProtections;
```

### 10.4 Training Requirements

```
Ethics Training Program:
1. Foundational Ethics (8 hours)
   - Ethical principles
   - Bioethics frameworks
   - Augmentation-specific ethics

2. Consent Procedures (4 hours)
   - Informed consent elements
   - Capacity assessment
   - Documentation

3. Equity and Justice (4 hours)
   - Distributive justice
   - Access barriers
   - Anti-discrimination

4. Vulnerable Populations (4 hours)
   - Special protections
   - Surrogate consent
   - Community engagement

5. Practical Application (4 hours)
   - Case studies
   - Ethical dilemmas
   - Decision-making process

Certification:
- Written examination
- Practical assessment
- Annual recertification
- Continuing education (8 hours/year)
```

### 10.5 Monitoring and Compliance

```
Ongoing Monitoring:
- Quarterly ethics committee reviews
- Annual compliance audits
- Adverse event reporting
- Equity assessments
- Subject satisfaction surveys
- Community feedback

Compliance Metrics:
- Consent documentation completeness
- Ethics review timeliness
- Coercion incident rate
- Equity in access
- Adverse event frequency
- Complaint resolution
- Stakeholder satisfaction

Corrective Actions:
- Process improvements
- Additional training
- Policy revisions
- Individual counseling
- Certification suspension
- Public disclosure
```

---

## 11. References

### 11.1 Ethical Frameworks

1. Beauchamp, T.L. & Childress, J.F. (2019). *Principles of Biomedical Ethics* (8th ed.)
2. Habermas, J. (2003). *The Future of Human Nature*
3. Sandel, M.J. (2007). *The Case Against Perfection*
4. Fukuyama, F. (2002). *Our Posthuman Future*
5. Bostrom, N. & Savulescu, J. (2009). *Human Enhancement*

### 11.2 International Standards

1. UNESCO Universal Declaration on Bioethics and Human Rights (2005)
2. Council of Europe Oviedo Convention on Human Rights and Biomedicine (1997)
3. World Medical Association Declaration of Helsinki (2013)
4. Nuremberg Code (1947)
5. Belmont Report (1979)

### 11.3 Specific Issues

**Informed Consent**:
- Faden, R.R. & Beauchamp, T.L. (1986). *A History and Theory of Informed Consent*
- Appelbaum, P.S. (2007). Assessment of patients' competence to consent to treatment

**Enhancement Ethics**:
- President's Council on Bioethics (2003). *Beyond Therapy*
- Buchanan, A. (2011). *Better Than Human*

**Justice and Equity**:
- Daniels, N. (2008). *Just Health: Meeting Health Needs Fairly*
- Powers, M. & Faden, R. (2006). *Social Justice*

**Identity and Authenticity**:
- DeGrazia, D. (2005). *Human Identity and Bioethics*
- Elliott, C. (2003). *Better Than Well*

### 11.4 WIA Standards

- WIA-AUG-001: Human Augmentation General Standards
- WIA-AUG-013: Augmentation Safety
- WIA-AUG-014: Human-Machine Interface
- WIA-MED: Medical Device Standards
- WIA-DATA: Data Privacy and Rights

---

## Appendix A: Ethical Assessment Worksheet

```
Device/Augmentation: _______________
Date: _______________
Assessor: _______________

ETHICAL PRINCIPLES ASSESSMENT (Score 0-10 each)

1. Autonomy: ___
   □ Informed consent obtained
   □ Subject has capacity
   □ Free from coercion
   □ Right to withdraw respected

2. Beneficence: ___
   □ Expected benefits significant
   □ Benefits outweigh risks
   □ Quality of life improved
   □ Subject's values considered

3. Non-Maleficence: ___
   □ Risks minimized
   □ Safety standards met
   □ Harm prevention protocols
   □ Emergency procedures established

4. Justice: ___
   □ Fair access
   □ No discrimination
   □ Equitable distribution
   □ Social determinants considered

5. Dignity: ___
   □ Human worth respected
   □ No degradation/objectification
   □ Rights maintained
   □ Cultural values honored

6. Authenticity: ___
   □ Aligned with subject's values
   □ Identity preserved
   □ Narrative continuity maintained
   □ Self-alienation prevented

OVERALL ASSESSMENT:
Average Score: ___
Compliant (all ≥7.0): □ Yes □ No

CONCERNS:
1. _______________
2. _______________
3. _______________

RECOMMENDATIONS:
1. _______________
2. _______________
3. _______________

DECISION: □ Approve □ Conditional □ Deny

Signature: _______________ Date: _______________
```

## Appendix B: Consent Checklist

```
COMPREHENSIVE CONSENT CHECKLIST

Subject: _______________
Augmentation: _______________
Type: □ Therapeutic □ Restorative □ Enhancement □ Experimental

INFORMATION DISCLOSURE:
□ Nature and purpose of augmentation
□ Expected benefits
□ Material risks and complications
□ Long-term implications
□ Identity and authenticity impacts
□ Social and occupational consequences
□ Reversibility options and limitations
□ Alternatives (including no augmentation)
□ Costs and financial obligations
□ Right to refuse and withdraw

COMPREHENSION ASSESSMENT:
□ Capacity evaluation completed
□ Understanding verified
□ Appreciation confirmed
□ Reasoning demonstrated
□ Questions answered

VOLUNTARINESS:
□ Coercion screening completed
□ No undue influence detected
□ Decision freely made
□ Adequate time for decision
□ Independent counseling offered

SPECIAL CONSIDERATIONS:
□ Vulnerable population protections (if applicable)
□ Cultural/religious considerations addressed
□ Language access provided
□ Independent advocacy (if required)

DOCUMENTATION:
□ Consent form signed and dated
□ Information disclosure documented
□ Comprehension assessment recorded
□ Capacity evaluation on file
□ Cooling-off period confirmed
□ Witness attestation (if required)
□ Ethics committee approval (if required)

SIGNATURES:
Subject: _______________ Date: _______________
Witness: _______________ Date: _______________
Provider: _______________ Date: _______________
Ethics Officer: _______________ Date: _______________ (if required)
```

---

**弘益人間 (홍익인간) · Benefit All Humanity**

*WIA-AUG-012 Specification v1.0*
*© 2025 SmileStory Inc. / WIA*
*MIT License*
